摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

5-(3-chloro-phenyl)-3-(4-methyl-5-thiophen-2-yl-4H-[1,2,4]triazol-3-ylsulfanylmethyl)-[1,2,4]oxadiazole

中文名称
——
中文别名
——
英文名称
5-(3-chloro-phenyl)-3-(4-methyl-5-thiophen-2-yl-4H-[1,2,4]triazol-3-ylsulfanylmethyl)-[1,2,4]oxadiazole
英文别名
5-(3-Chlorophenyl)-3-[(4-methyl-5-thiophen-2-yl-1,2,4-triazol-3-yl)sulfanylmethyl]-1,2,4-oxadiazole
5-(3-chloro-phenyl)-3-(4-methyl-5-thiophen-2-yl-4H-[1,2,4]triazol-3-ylsulfanylmethyl)-[1,2,4]oxadiazole化学式
CAS
——
化学式
C16H12ClN5OS2
mdl
——
分子量
389.889
InChiKey
SZUCSNVBBXGZNK-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    3.7
  • 重原子数:
    25
  • 可旋转键数:
    5
  • 环数:
    4.0
  • sp3杂化的碳原子比例:
    0.12
  • 拓扑面积:
    123
  • 氢给体数:
    0
  • 氢受体数:
    7

文献信息

  • Additional heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists
    申请人:Edwards Louise
    公开号:US20050272779A1
    公开(公告)日:2005-12-08
    The present invention relates to new compounds of formula I, to pharmaceutical formulations containing the compounds, and to the use of the compounds in the prevention and/or treatment of mGluR5 receptor-mediated disorders.
    本发明涉及公式I的新化合物,包含该化合物的药物配方,以及利用该化合物预防和/或治疗mGluR5受体介导的疾病的用途。
  • [EN] 7-ARYL-3,9-DIAZABICYCLO(3.3.1)NON-6-ENE DERIVATIVES AND THEIR USE AS RENIN INHIBITORS IN THE TREATMENT OF HYPERTENSION, CARDIOVASCULAR OR RENAL DISEASES<br/>[FR] DERIVES DE 7-ARYL-3,9-DIAZABICYCLO(3.3.1)NON-6-ENE ET LEUR UTILISATION EN TANT QU'INHIBITEURS DE RENINE DANS LE TRAITEMENT DE L'HYPERTENSION, DE MALADIES CARDIOVASCULAIRES OU RENALES
    申请人:ACTELION PHARMACEUTICALS LTD
    公开号:WO2003093267A1
    公开(公告)日:2003-11-13
    The invention relates to novel 3,9-diazabicyclo[3.3.1]nonene derivatives of formula (I) and related compounds and their use as active ingredients in the preparation of pharmaceutical compositions. The invention also concerns related aspects including processes for the preparation of the compounds, pharmaceutical compositions containing one or more of those compounds and especially their use as inhibitors or renin.
    该发明涉及新型3,9-二氮杂双环[3.3.1]壬烯生物(I)及相关化合物,以及它们作为药物组合物中活性成分的用途。该发明还涉及相关方面,包括制备这些化合物的过程、含有这些化合物中的一个或多个的药物组合物,尤其是它们作为肾素抑制剂的用途。
  • Compounds
    申请人:Arora Jalaj
    公开号:US20060122397A1
    公开(公告)日:2006-06-08
    The present invention relates to new compounds of formula I, a process for their preparation and new intermediates prepared therein, pharmaceutical formulations containing said compounds and to the use of said compounds in therapy.
    本发明涉及化合物I的新化合物,其制备过程和其中制备的新中间体,含有该化合物的制药配方以及在治疗中使用该化合物的用途。
  • ADDITIONAL HETEROPOLYCYCLIC COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS
    申请人:Edwards Louise
    公开号:US20080045571A1
    公开(公告)日:2008-02-21
    The present invention relates to new compounds of formula I, to pharmaceutical formulations containing the compounds, and to the use of the compounds in the prevention and/or treatment of mGluR5 receptor-mediated disorders.
    本发明涉及公式I的新化合物,包括含有该化合物的制药配方,以及该化合物在预防和/或治疗mGluR5受体介导的疾病中的使用。
  • 7-ARYL-3,9-DIAZABICYCLO[3.3.1]NON-6-ENE DERIVATIVES AND THEIR USE AS RENIN INHIBITORS IN THE TREATMENT OF HYPERTENSION, CARDIOVASCULAR OR RENAL DISEASES
    申请人:Actelion Pharmaceuticals Ltd.
    公开号:EP1501830A1
    公开(公告)日:2005-02-02
查看更多